A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Francesco Passamonti(University of Pavia), Francisco Cervantes(Universitat de Barcelona), Alessandro M. Vannucchi(University of Florence), Enrica Morra(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Elisa Rumi(University of Pavia), Arturo Pereira(Universitat de Barcelona), Paola Guglielmelli(University of Florence), Ester Pungolino(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Marianna Caramella(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Margherita Maffioli(Universitat de Barcelona), Cristiana Pascutto(University of Pavia), Mario Lazzarino(University of Pavia), Mario Cazzola(University of Pavia), Ayalew Tefferi(Mayo Clinic in Arizona)
Blood
December 15, 2009
Cited by 965Open Access
Full Text

Abstract

Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.


Related Papers